[Anti-interleukin-5 therapy for eosinophilic diseases]

Simon, D; Braathen, L R; Simon, H-U (2007). [Anti-interleukin-5 therapy for eosinophilic diseases]. Hautarzt, 58(2), 122, 124-7. Heidelberg: Springer-Verlag 10.1007/s00105-006-1273-x

Preview

Text 105_2006_Article_1273.pdf - Published Version Available under License Publisher holds Copyright. Download (440kB) | Preview

In a number of diseases with eosinophilia, elevated interleukin (IL)-5 levels are detected in the peripheral blood and/or tissues. IL-5 plays an important role in regulating the production, differentiation, recruitment, activation, and survival of eosinophils. Therefore, neutralizing IL-5 by blocking antibodies seems a promising approach in the treatment of eosinophilic diseases. Clinical trials have demonstrated that anti-IL-5 therapy results in a rapid decrease in peripheral blood eosinophil numbers. Moreover, improvement of symptoms in patients with lymphocytic variants of hypereosinophilic syndromes, in eosinophilic esophagitis and chronic rhinitis with nasal polyposis has been observed. In contrast, in patients with bronchial asthma or atopic eczema, anti-IL-5 therapy showed only moderate or no clinical effects. Future studies will have to identify those eosinophilic diseases in which anti-IL-5 antibodies are effective, perhaps with the help of newly developed biomarkers.

Interest & Impact

Downloads

982 since deposited on 04 Oct 2013
193 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item